Tag: $Moderna

Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business.

Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. 

Moderna announced positive clinical trial data on three experimental vaccines and said it will move those shots to final stage studies.

Moderna posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. 

Moderna on Thursday unveiled new data from a continuing early-stage trial of the personalized cancer treatment it is testing with Merck, saying that the updated results help build the case that the drug works.

Moderna posted a loss for the third quarter as demand for its Covid shots declined.

Moderna stock was rising Wednesday after the vaccine maker released positive results from a Phase 3 trial of its mRNA flu vaccine and provided insight on its plans for other vaccines targeting cancer and other diseases

Moderna’s new Covid vaccine generated a strong immune response against BA.2.86, a highly mutated omicron variant that health officials are watching closely, according to clinical trial data the biotech company released Wednesday.

Moderna’s new Covid vaccine generated a robust immune response against the now-dominant Eris variant and another rapidly spreading strain of the virus in an early clinical trial, the biotech company said Thursday. 

Moderna shares were rising early Thursday after the company reported lighter losses and better revenue than expected for the June quarter and raised guidance for sales of its Covid-19 vaccine.